

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

22-042

APPROVAL LETTER



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 22-042
NDA 20-815/S-025

NDA APPROVAL

Eli Lilly and Company
Attention: Daniel R. Brady, Ph.D., RAC
Manager, US Regulatory Affairs
Lilly Corporate Center
Indianapolis, IN 46285

Dear Dr. Brady:

Please refer to your new drug application (NDA) dated November 13, 2006, received November 14, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Evista® (raloxifene hydrochloride) Tablets, 60 mg.

We acknowledge receipt of your submissions dated December 11 and 18, 2006 and February 9 and 12, March 13 and 14, April 12, May 10, 14, 21, 24, and 31, June 5 and 19, July 20, August 3, 15, and 31, and September 7, 2007. We also refer to your submission dated September 5, 2007 to NDA 20-815 supplement 025, which cross references NDA 22-042. Please note that the enclosed labeling supersedes the August 31, 2007 label referenced in NDA 20-815 supplement 025.

This new drug application provides for the use of Evista® (raloxifene hydrochloride) for reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed labeling (text for the package insert and Medication Guide). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 22-042."

We acknowledge your agreement to submit final printed carton and container labels, which are in compliance with 21 CFR 208.24 (d), as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005).

Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "Final Printed Carton and Container Labels for approved NDA 22-042." Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see www.fda.gov/cder/ddmac.

If you issue a letter communicating important safety related information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
HFD-001, Suite 5100
5515 Security Lane
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

All 15-day alert reports, periodic (including quarterly) adverse drug experience reports, field alerts, annual reports, supplements, and other submissions should be addressed to the original NDA 20-815 for this drug product, not to this NDA. In the future, do not make submissions to this NDA except for the final printed labeling requested above.

NDA 22-042
NDA 20-815/S-025
Page 3

If you have any questions, call Patricia Garvey, Senior Regulatory Project Manager, at (301) 796-1356.

Sincerely,

{See appended electronic signature page}

Robert L. Justice, M.D.
Director
Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

Enclosure

Appears This Way
On Original

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Robert Justice
9/13/2007 06:59:27 PM

Appears This Way
On Original